FRCPath Haem Part 1 MCQ-Haemostasis 73

25-year old male with sever hemophilia A without inhibitor is switched from factor VIII prophylaxis to emicizumab. Which statement about Emicizumab is correct?

• Routine factor VIII level monitoring with standard one-stage
• May interfere with one-stage clotting assays
• Patients require daily aPTT monitoring
• Anti-drug antibodies do not develop with emicizumab

See All Options